Anavex Life Sciences Corp
$ 2.57
-8.87%
05 Jun - close price
- Market Cap 238,166,000 USD
- Current Price $ 2.57
- High / Low $ 2.82 / 2.56
- Stock P/E N/A
- Book Value 1.37
- EPS -0.46
- Next Earning Report 2026-06-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.34 %
- 52 Week High 13.99
- 52 Week Low 2.56
About
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
Analyst Target Price
$20.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-26 | 2026-02-09 | 2025-11-25 | 2025-08-12 | 2025-05-13 | 2025-02-12 | 2024-12-23 | 2024-08-06 | 2024-05-09 | 2024-02-07 | 2023-11-27 | 2023-08-08 |
| Reported EPS | 0 | -0.06 | -0.11 | -0.16 | -0.13 | -0.14 | -0.14 | -0.14 | -0.13 | -0.11 | -0.12 | -0.14 |
| Estimated EPS | -0.07 | -0.11 | -0.1426 | -0.14 | -0.15 | -0.17 | -0.17 | -0.18 | -0.13 | -0.15 | -0.15 | -0.17 |
| Surprise | 0.07 | 0.05 | 0.0326 | -0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0 | 0.04 | 0.03 | 0.03 |
| Surprise Percentage | 100% | 45.4545% | 22.8612% | -14.2857% | 13.3333% | 17.6471% | 17.6471% | 22.2222% | 0% | 26.6667% | 20% | 17.6471% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-06-09 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVXL
2026-06-04 06:10:19
The technical analysis for Anavex Life Sciences Corp (AVXL) indicates a "Strong Sell" consensus, aggregating 12 technical signals. Key indicators like MACD and several moving averages suggest bearish momentum, while the RSI is in a neutral range. The stock is trading below its 20-day, 60-day, and 200-day simple moving averages, with critical support at $2.584 and resistance at $3.044.
2026-05-23 05:10:11
Anavex Life Sciences (AVXL) has received an expected notification from Nasdaq regarding its delinquency in filing its quarterly report on Form 10-Q for the quarter ended March 31, 2026. This notification is a routine procedural matter and does not affect the company's listing or operations. Anavex was granted a 60-day extension until July 22, 2026, to submit a plan for regaining compliance.
2026-05-22 17:40:18
Anavex Life Sciences Corp. received a Nasdaq delisting warning for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan. Despite this, Anavex is actively developing therapies for central nervous system disorders, including its Alzheimer's drug candidate blarcamesine, and recently appointed an interim CEO.
2026-05-22 17:39:05
Anavex Life Sciences Corp. announced it received a delinquency notification from Nasdaq because it has not yet filed its quarterly report on Form 10-Q for the period ended March 31, 2026. This notification indicates non-compliance with Nasdaq's continued listing requirements, specifically Listing Rule 5250(c)(1). The company has until July 22, 2026, to submit a plan to regain compliance, but this notification does not currently affect the listing or trading of its securities.
2026-05-22 17:09:31
Anavex Life Sciences (NASDAQ:AVXL) received a delinquency notification from Nasdaq due to its failure to timely file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan. Despite this, the stock is considered undervalued by InvestingPro, and the company recently appointed an Interim CEO and is active in developing treatments for CNS disorders.
2026-05-22 12:38:54
Anavex Life Sciences (AVXL) received a notice of noncompliance from Nasdaq on May 20, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company's stock continues to trade on the Nasdaq Global Select Market, and it has until July 20, 2026, to submit a compliance plan. If the plan is accepted, Anavex may have until November 16, 2026, to regain compliance.
